Close Menu

NEW YORK — Grail, a developer of early cancer detection technologies, on Wednesday filed with the US Securities and Exchange Commission to go public on the Nasdaq.

The Menlo Park, California-based company did not specify the number of shares it intends to float or a price range for the proposed initial public offering. Morgan Stanley, Goldman Sachs, and BofA Securities will act as lead bookrunners of the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.